Back to Screener

Healthcare

Gedeon Richter PLC(GEDSF)

Live Price

Offline

$24.85

+0.00% today

1Y Change

+0.00%

Window

Jun 25, 2025 โ†’ Jun 23, 2026

Market Cap
$2.39T
Revenue Growth
+0.6%
EPS Growth
-9.8%
Dividend Yield
3.9%

Coverage: 252 bars ยท Jun 25, 2025 โ†’ Jun 23, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Gedeon Richter PLC (GEDSF) is a Healthcare stock with a market cap of $2.39T and listed on OTC. The stock last traded around $24.85 and up 0.0% across the available one-year price window (Jun 25, 2025 โ†’ Jun 23, 2026). Baseline metrics include revenue growth of +0.6%, EPS growth of -9.8%, a dividend yield of 3.9%. What stands out right now is revenue +0.6%, EPS -9.8%, free cash flow +7.5% with operating margin 33.2% and ROIC 16.6%. The dividend matters to the case here, with a current yield around 3.9%. Valuation is more restrained than many high-expectation growth names at P/E 10.3 and price/sales 2.6. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines GEDSF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Sector Context

How this name stacks up against nearby peers on first-pass metrics.

Revenue Growth

Below sector median

+0.6% vs +7.6% peer median

Operating Margin

Above sector median

+33.2% vs +19.4% peer median

P/E

Below sector median

10.3 vs 36.3 peer median

What Changed This Quarter

Latest report context and the signals most likely to have changed the story.

Latest report is on the board

2026 was reported on May 11, 2026, but the surprise data is still limited.

The operating picture looks softer than before

Revenue is at +0.6% and EPS is at -9.8%, with operating margin around 33.2%.

Shareholder return is still part of the story

The stock is still offering a dividend yield around 3.9%, which matters if the thesis depends on income as much as growth.

Earnings Reaction Memory

How the stock has tended to move after recent reports.

Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.

View quarter-by-quarter reaction table
QuarterEPS ฮ”1D5D20D
2026
May 11, 2026
โ€”+0.0%+0.0%+0.0%
2026
Feb 26, 2026
โ€”+0.0%+0.0%+0.0%
2025
Nov 6, 2025
โ€”+0.0%+0.0%+0.0%

Benchmark Edge

GEDSF vs SPY, QQQ, and Sector ETFs

Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.

Shared 1Y chart + MAX history table

GEDSF

โ€”

Normalized return

SPY

--

S&P 500

Excess Return

--

Relative to SPY

GEDSF Max Drawdown

0.00%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for GEDSF and SPY.

Calendar-year return history is still loading or unavailable.
Gedeon Richter PLC logo

Company Overview

Gedeon Richter PLC

Other OTC

Chemical Works of Gedeon Richter Plc engages in the development and manufacture of pharmaceuticals. It operates through the following segments: Pharmaceuticals, Wholesale & Retail, and Others. The Pharmaceutical segment engages in research and development, manufacturing, sales and marketing of pharmaceutical products. The Wholesale & Retail segment represents the distribution of companies and pharmacies that are part of the sales network in various regional markets and, as such, convey its products to consumers. The Other segment relates to the business of the members of the group that provide marketing and sales support services. The company was founded by Gedeon Richter in 1901 and is headquartered in Budapest, Hungary.

Leadership
Gabor Orban
IPO Date
Jan 3, 2000
Employees
10.9k
Street Address
GyOemroi Ut 19-21.
Mailing
Budapest, 1103
Region
Budapest, HU
Reporting Currency
USD
Investor Line
36 1 431 4000
Last Updated
Apr 29, 2026
ISIN: US3684672054
Reports in USD

Key Fundamentals

Valuation, growth, profitability, and balance sheet signals.

Valuation

P/E
10.3
EV/EBITDA
6.4
Price/Sales
2.6
Price/Book
1.7

Growth

Revenue
+0.6%
EPS
-9.8%
Free Cash Flow
+7.5%

Profitability

Gross Margin
68.1%
Operating Margin
33.2%
Net Margin
25.0%
ROE
17.3%
ROIC
16.6%

Balance Sheet

Debt/Equity
0.03
Current Ratio
4.51

Earnings Reports

๐Ÿ“… Last reportedMay 11, 2026
PeriodB/MEPSEPS ฮ”RevenueRev ฮ”
โ€”
May 11, 26
โ€”
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Feb 26, 26
1.13
Est โ€”
โ€”
744828.9B
Est โ€”
โ€”
โ€”
Nov 6, 25
โ€”
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
May 13, 25
373.00
Est โ€”
โ€”
224024000.0B
Est โ€”
โ€”
โ€”
Feb 28, 25
โ€”
Est โ€”
โ€”
โ€”
Est 224993500.0B
โ€”
โ€”
Nov 12, 24
โ€”
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Aug 6, 24
382.92
Est โ€”
โ€”
216261000.0B
Est โ€”
โ€”
โ€”
Apr 25, 24
373.00
Est โ€”
โ€”
203432000.0B
Est โ€”
โ€”
โ€”
Feb 29, 24
294.00
Est โ€”
โ€”
188544000.0B
Est โ€”
โ€”
โ€”
Dec 31, 23
197.00
Est โ€”
โ€”
203178000.0B
Est โ€”
โ€”
โ€”
Jun 30, 23
155.26
Est โ€”
โ€”
203783000.0B
Est โ€”
โ€”
โ€”
Mar 31, 23
210.00
Est โ€”
โ€”
209653000.0B
Est โ€”
โ€”
โ€”
Dec 31, 22
-144.55
Est โ€”
โ€”
223968000.0B
Est โ€”
โ€”
โ€”
Sep 30, 22
442.00
Est โ€”
โ€”
217807000.0B
Est โ€”
โ€”
โ€”
Jun 30, 22
411.00
Est โ€”
โ€”
192923000.0B
Est โ€”
โ€”
โ€”
Mar 31, 22
199.00
Est โ€”
โ€”
168057000.0B
Est โ€”
โ€”

Latest News

No news articles available

Official Releases

Company announcements and filings-style updates.

Official
No official releases available

Next Step

Keep the research moving

After the overview, the strongest next step is usually chart context or a tighter compare set.